Effect of Semaglutide 0.25mg on glycemic controls in type2 diabetes patients compared with dulaglutide 0.75mg.
Not Applicable
Recruiting
- Conditions
- type2 diabetes
- Registration Number
- JPRN-UMIN000042482
- Lead Sponsor
- Saiseikai Yokohamashi Nanbu Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pationts received insulin 2) Patients with severe liver dysfunction 3) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 4) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 5) Patients taking steroid 6) Patients with malignant tumor currently undergoing treatment 7) Pregnant or lactating woman 8) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patients are goint to stop receiving dulaglutide 0.75mg and start receiving semaglutide 0.25mg. We compare HbA1c levels before receiving semaglutide 0.25mg with those after receiving semaglutide 0.25mg in 12 weeks.
- Secondary Outcome Measures
Name Time Method